Compare Novartis with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs CADILA HEALTHCARE - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS CADILA HEALTHCARE NOVARTIS/
CADILA HEALTHCARE
 
P/E (TTM) x 915.4 22.0 4,154.5% View Chart
P/BV x 27.5 2.6 1,045.3% View Chart
Dividend Yield % 1.6 1.3 122.5%  

Financials

 NOVARTIS   CADILA HEALTHCARE
EQUITY SHARE DATA
    NOVARTIS
Mar-19
CADILA HEALTHCARE
Mar-19
NOVARTIS/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs980432 226.6%   
Low Rs600306 195.9%   
Sales per share (Unadj.) Rs198.7128.6 154.5%  
Earnings per share (Unadj.) Rs21.018.5 113.1%  
Cash flow per share (Unadj.) Rs22.324.4 91.2%  
Dividends per share (Unadj.) Rs10.003.50 285.7%  
Dividend yield (eoy) %1.30.9 133.6%  
Book value per share (Unadj.) Rs307.5101.5 303.1%  
Shares outstanding (eoy) m24.691,023.74 2.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.02.9 138.4%   
Avg P/E ratio x37.719.9 189.2%  
P/CF ratio (eoy) x35.515.1 234.4%  
Price / Book Value ratio x2.63.6 70.6%  
Dividend payout %47.718.9 252.7%   
Avg Mkt Cap Rs m19,508378,170 5.2%   
No. of employees `0000.612.4 4.7%   
Total wages/salary Rs m1,17121,241 5.5%   
Avg. sales/employee Rs Th8,445.410,585.0 79.8%   
Avg. wages/employee Rs Th2,015.71,707.8 118.0%   
Avg. net profit/employee Rs Th891.01,526.5 58.4%   
INCOME DATA
Net Sales Rs m4,907131,656 3.7%  
Other income Rs m7832,011 38.9%   
Total revenues Rs m5,689133,667 4.3%   
Gross profit Rs m12329,731 0.4%  
Depreciation Rs m325,986 0.5%   
Interest Rs m161,935 0.8%   
Profit before tax Rs m85823,821 3.6%   
Minority Interest Rs m0469 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3405,303 6.4%   
Profit after tax Rs m51818,987 2.7%  
Gross profit margin %2.522.6 11.1%  
Effective tax rate %39.622.3 178.1%   
Net profit margin %10.614.4 73.2%  
BALANCE SHEET DATA
Current assets Rs m8,05584,981 9.5%   
Current liabilities Rs m1,85073,425 2.5%   
Net working cap to sales %126.48.8 1,440.6%  
Current ratio x4.41.2 376.2%  
Inventory Days Days4575 60.4%  
Debtors Days Days34110 31.0%  
Net fixed assets Rs m150133,493 0.1%   
Share capital Rs m1231,024 12.1%   
"Free" reserves Rs m7,469102,839 7.3%   
Net worth Rs m7,592103,863 7.3%   
Long term debt Rs m039,497 0.0%   
Total assets Rs m9,824234,831 4.2%  
Interest coverage x54.913.3 412.8%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.50.6 89.1%   
Return on assets %5.48.9 61.0%  
Return on equity %6.818.3 37.3%  
Return on capital %11.518.3 62.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5848,404 0.1%   
Fx outflow Rs m1,32611,593 11.4%   
Net fx Rs m-1,26936,811 -3.4%   
CASH FLOW
From Operations Rs m-1,94328,823 -6.7%  
From Investments Rs m2,742-57,387 -4.8%  
From Financial Activity Rs m-29818,846 -1.6%  
Net Cashflow Rs m501-7,105 -7.1%  

Share Holding

Indian Promoters % 0.0 74.8 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 8.3 24.1%  
FIIs % 1.6 5.9 27.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 11.0 195.5%  
Shareholders   41,647 44,069 94.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   IPCA LABS  GSK PHARMA  DR. DATSONS LABS  PROCTER & GAMBLE HEALTH  SANOFI INDIA  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Moody's GDP Growth Forecast, Slump in Equity Mutual Fund Inflows, and Top Cues in Focus Today(Pre-Open)

India share markets witnessed selling pressure during closing hours yesterday and ended on a negative note.

Related Views on News

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

Buy this 'Crorepati Stock' and You Could End Up Stinking Rich(Profit Hunter)

Feb 5, 2020

I'm talking about an individual small cap stock that could go up so many times that they make their investors stinking rich in the process. You definitely want to know more...

This Smallcap Stock Could be the Next Titan (Up 1,400% in 10 Years)(Profit Hunter)

Feb 11, 2020

A blueprint to latch on to the next 'Crorepati' stock - and an event I hope you won't miss on any account.

Will Your Trade Go Up or Down Today?(Fast Profits Daily)

Feb 5, 2020

How you can find out which way your trade is likely to move on any given trading day.

Will Algo Traders Take Away All Your Profits?(Fast Profits Daily)

Feb 11, 2020

How to fight back against algo trading systems.

No Change in My Long-Term View on the Rebirth of India Stocks(The 5 Minute Wrapup)

Feb 6, 2020

Why the recent post budget volatility has not affected my bullish view on the Rebirth of India stocks.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Feb 17, 2020 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS